Literature DB >> 25227284

Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.

Chandrasekar Durairaj1.   

Abstract

BACKGROUND AND
OBJECTIVE: Effective control of intraocular pressure (IOP) is essential for the successful management of glaucoma. IOP exhibits diurnal variation, yet continuous monitoring is impractical. To date, no clear evidence exists on the number of sampling timepoints required to characterize diurnal IOP and when those measurements should be collected. The objective of this study was to develop an optimized sampling scheme to estimate diurnal IOP and to provide sampling windows for practicality.
METHODS: Baseline IOP values for glaucoma patients were collected from the published literature. A population model-based meta-analysis was performed to develop a model for diurnal IOP that accounts for covariates and inter-study variability. Optimization was performed using the D-optimality criteria to determine optimal sampling times. In addition, various reduced sampling designs were tested to investigate the minimum number of sampling timepoints to precisely estimate diurnal IOP. Also, sampling windows were calculated around the final optimal sampling times to allow flexibility in data collection. The final reduced optimized model was validated by simulating and estimating 500 datasets with reduced optimal sampling times.
RESULTS: The final baseline IOP model included type of glaucoma as a covariate. Bootstrap analysis and visual predictive check plots revealed the adequacy of the model to describe the observed IOP data. Optimization results indicated an increasing trend in bias with decreasing sampling timepoints. A reduced model with four sampling times resulted in acceptable precision (<40 %). Restricting the sampling time between 8 a.m. and 4 p.m. underestimates the fluctuation in diurnal IOP. Sampling windows with ≥95 % efficiency were calculated around the optimized sampling times. Validation results indicated acceptable precision and relative bias for model estimates in the reduced optimized model.
CONCLUSION: A physiologically based mechanistic model was developed to describe the diurnal variation in baseline IOP and inter-study variability was estimated on key diurnal model parameters. Optimization of the final covariate model indicated a reduced sampling time of at least four samples should be collected at 5:45 a.m., 2:15 p.m., 8:00 p.m., and 12:00 a.m. for reliable estimation of diurnal IOP variation.

Entities:  

Mesh:

Year:  2015        PMID: 25227284     DOI: 10.1007/s40262-014-0183-9

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  45 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 3.  Exfoliation syndrome and exfoliation glaucoma.

Authors:  E Vesti; T Kivelä
Journal:  Prog Retin Eye Res       Date:  2000-05       Impact factor: 21.198

4.  Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy.

Authors:  Anastasios G P Konstas; Kostantinos Boboridis; Despina Tzetzi; Kostantinos Kallinderis; Jessica N Jenkins; William C Stewart
Journal:  Arch Ophthalmol       Date:  2005-07

5.  24-Hour control with a latanoprost-timolol fixed combination vs timolol alone.

Authors:  Anastasios G P Konstas; Symeon Lake; Athanasios I Economou; Kostantinos Kaltsos; Jessica N Jenkins; William C Stewart
Journal:  Arch Ophthalmol       Date:  2006-11

6.  Twenty-four-hour pattern of intraocular pressure in untreated patients with ocular hypertension.

Authors:  Tomas M Grippo; John H K Liu; Nazlee Zebardast; Taylor B Arnold; Grant H Moore; Robert N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

7.  Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.

Authors:  Anastasios G P Konstas; Gábor Holló; Dimitrios Mikropoulos; Sevasti Tsironi; Anna-Bettina Haidich; Theodoros Embeslidis; Irene Georgiadou; Murat Irkec; Shlomo Melamed
Journal:  Br J Ophthalmol       Date:  2009-10-12       Impact factor: 4.638

8.  A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.

Authors:  F Topouzis; S Melamed; H Danesh-Meyer; A P Wells; V Kozobolis; H Wieland; R Andrew; D Wells
Journal:  Eur J Ophthalmol       Date:  2007 Mar-Apr       Impact factor: 2.597

9.  Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes.

Authors:  John H K Liu; Xiaoyan Zhang; Daniel F Kripke; Robert N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-04       Impact factor: 4.799

10.  Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.

Authors:  William C Stewart; Anastasios G P Konstas; Lindsay A Nelson; Bonnie Kruft
Journal:  Ophthalmology       Date:  2008-02-20       Impact factor: 12.079

View more
  3 in total

Review 1.  Advances in diagnostic applications for monitoring intraocular pressure in Glaucoma: A review.

Authors:  Irene Sanchez; Raul Martin
Journal:  J Optom       Date:  2019-08-10

2.  Applications of Model-Based Meta-Analysis in Drug Development.

Authors:  Phyllis Chan; Kirill Peskov; Xuyang Song
Journal:  Pharm Res       Date:  2022-02-16       Impact factor: 4.580

Review 3.  Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.

Authors:  Uday B Kompella; Rachel R Hartman; Madhoosudan A Patil
Journal:  Prog Retin Eye Res       Date:  2020-09-04       Impact factor: 21.198

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.